Table 1.

Overview of published and evaluated prognostic signatures for prostate cancer used for our study.

Acronym of a study	Number of genes*	Cancer type	Reference
AGELL	12	Prostate cancer	Agell et al., 2012
BIBIKOVA	16	Prostate cancer	Bibikova et al., 2007
BISMAR	12	Prostate cancer	Bismar et al., 2006
CHEN	4	Prostate cancer	Chen et al., 2020
CHEN_CC	7	Prostate cancer	Chen et al., 2012
CHEVILLE	2	Prostate cancer	Cheville et al., 2008
CHU	8	Prostate cancer	Chu et al., 2018
CUZICK	31	Prostate cancer	Cuzick et al., 2011
GLINSKY	11	Multiple cancers	Glinsky et al., 2005
IRSHAD	19	Prostate cancer	Irshad et al., 2013
IRSHAD_1	3	Prostate cancer	Irshad et al., 2013
LARKIN	7	Prostate cancer	Larkin et al., 2012
LI	6	Prostate cancer	Li et al., 2019
LIU	167	Multiple cancers	Liu et al., 2007
LONG	12	Prostate cancer	Long et al., 2011
NAKAGAWA	17	Prostate cancer	Nakagawa et al., 2008
PENNEY	157	Prostate cancer	Penney et al., 2011
RAMASWAMY	16	Multiple cancers	Ramaswamy et al., 2003
REDDY	16	Prostate cancer	Reddy and Balk, 2006
ROSS-ADAMS	100	Prostate cancer	Ross-Adams et al., 2015
ROSS	6	Prostate cancer	Ross et al., 2012
SAAL	162	Multiple cancers	Saal et al., 2007
SHARMA	15	Prostate cancer	Sharma et al., 2013
SINGH	5	Prostate cancer	Singh et al., 2002
SONG	15	Prostate cancer	Song et al., 2019
STEPHENSON	10	Prostate cancer	Stephenson et al., 2005
TALANTOV	3	Prostate cancer	Talantov et al., 2010
TANDEFELT	36	Prostate cancer	Tandefelt et al., 2013
TRUE	86	Prostate cancer	True et al., 2006
WANG	43	Prostate cancer	Wang et al., 2017
WU	29	Prostate cancer	Wu et al., 2013
YU	14	Multiple cancers	Yu et al., 2007

Number of genes^* corresponds to the number of genes in a signature after conversion from HGNC gene symbols to Entrez gene IDs.